Orjuela 2019a - Revision history

Maorjuelaro at 03:54, 9 April 2020

2020-04-09T03:54:43Z

Maorjuelaro at 03:53, 9 April 2020

2020-04-09T03:53:16Z

Maorjuelaro at 03:51, 9 April 2020

2020-04-09T03:51:56Z

Maorjuelaro at 03:50, 9 April 2020

2020-04-09T03:50:25Z

Maorjuelaro at 03:48, 9 April 2020

2020-04-09T03:48:58Z

Maorjuelaro at 03:45, 9 April 2020

2020-04-09T03:45:08Z

Maorjuelaro at 03:42, 9 April 2020

2020-04-09T03:42:38Z

Maorjuelaro at 03:30, 9 April 2020

2020-04-09T03:30:59Z

Maorjuelaro at 03:29, 9 April 2020

2020-04-09T03:29:16Z

Show changes

Maorjuelaro: Maorjuelaro moved page Draft Orjuela 569805274 to Orjuela 2019a

2019-05-31T22:54:21Z

Maorjuelaro moved page Draft Orjuela 569805274 to Orjuela 2019a

@@ Line 23: / Line 23: @@
 Tabla 1. Antifúngicos azólicos más comunes.
-[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|292x292px]]
+[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|311x311px]]
 .1 Mutaciones puntuales de ERG11

@@ Line 23: / Line 23: @@
 Tabla 1. Antifúngicos azólicos más comunes.
-[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|285x285px]]
+[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|292x292px]]
 .1 Mutaciones puntuales de ERG11
@@ Line 48: / Line 48: @@
 En la actualidad se considera que uno de cada cuatro aislados de especies de Candida presentan algún tipo de resistencia a los fármacos, incluso en la actualidad son descubiertas nuevas especies como ''Candida auris'', que desde su aparición en entornos clínicos ya presenta resistencia a los antifúngicos, este escenario conlleva a replantearse la necesidad de aumentar los recursos destinados a investigación tanto en nuevas moléculas antifúngicas como en el estudio de los mecanismos de acción que generan resistencia, así como factores de virulencia que facilitan la infección y colonización del huésped. Las ciencias ómicas representan una oportunidad para explorar genomas y transcriptomas completos tal que se puedan explorar los cambios a nivel genético y los procesos causantes de resistencia y que a su vez permitan el desarrollo de nuestras estrategias para enfrentar la resistencia.
 ==References==
-==3 Bibliography<!--
-−
-El-Houssaini, H. H., Elnabawy, O. M., Nasser, H. A., & Elkhatib, W. F. (2019). Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. Microbial pathogenesis, 128, 13-19.
-−
-Girão, E., Levin, A. S., Basso, M., Gobara, S., Gomes, L. B., Medeiros, E. A. S., ... & Costa, S. F. (2008). Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999–2003. International Journal of Infectious Diseases, 12(6), e145-e146.
-−
-Hoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011). An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrobial agents and chemotherapy, 55(2), 940-942.
-−
-Kelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995). Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8, 24 (28)-dien-3β, 6α-diol. Biochemical and biophysical research communications, 207(3), 910-915.
-−
-Kohli, A., Smriti, N. F. N., Mukhopadhyay, K., Rattan, A., & Prasad, R. (2002). In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrobial agents and chemotherapy, 46(4), 1046-1052.
-−
-Marichal, P., Bossche, H. V., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V., ... & Mose-Larsen, P. (1997). Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy, 41(10), 2229-2237.
-−
-Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010). Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagnostic microbiology and infectious disease, 66(4), 373-384.
-−
-Mukhopadhyay, K., Prasad, T., Saini, P., Pucadyil, T. J., Chattopadhyay, A., & Prasad, R. (2004). Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrobial Agents and Chemotherapy, 48(5), 1778-1787.
-−
-Nikaido, Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria, FASEB J. 12 (1998) 265–274.
-−
-Noël, T. (2012). The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. Journal de mycologie medicale, 22(2), 173-178.
-−
-Pourakbari, B., Teymuri, M., Mahmoudi, S., K Valian, S., Movahedi, Z., Eshaghi, H., & Mamishi, S. (2017). Expression of Major Efflux Pumps in Fluconazole-Resistant Candida albicans. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 17(3), 178-184.
-−
-Selmecki, A., Forche, A., & Berman, J. (2006). Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science, 313(5785), 367-370.
-−
-Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012). Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS microbiology reviews, 36(2), 288-305.
-−
-Silver, P. M., Oliver, B. G., & White, T. C. (2004). Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryotic Cell, 3(6), 1391-1397.
-−
-Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 2003;51:1055–65.
-−
-White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial agents and chemotherapy, 41(7), 1482-1487.
-−
-Wille, M. P., Guimarães, T., Furtado, G. H. C., & Colombo, A. L. (2013). Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil. Memorias do Instituto Oswaldo Cruz, 108(3), 288-292.
-−
-Wirsching, S., Michel, S., & Morschhäuser, J. (2000). Targeted gene disruption in Candida albicans wild‐type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Molecular microbiology, 36(4), 856-865.
-−
-Yapar, N., Pullukcu, H., Avkan-Oguz, V., Sayin-Kutlu, S., Ertugrul, B., Sacar, S., ... & Kaya, O. (2011). Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Medical mycology, 49(1), 26-31.
-−
-==4 Acknowledgments<!-- Acknowledgments should be inserted at the end of the document, before the references section. -->==
-−
-−
-−
-−
-==5 References==
 El-Houssaini, H. H., Elnabawy, O. M., Nasser, H. A., & Elkhatib, W. F. (2019). Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. Microbial pathogenesis, 128, 13-19.

@@ Line 23: / Line 23: @@
 Tabla 1. Antifúngicos azólicos más comunes.
-[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|267x267px]]
+[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|285x285px]]
 .1 Mutaciones puntuales de ERG11

@@ Line 23: / Line 23: @@
 Tabla 1. Antifúngicos azólicos más comunes.
-[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|355x355px]]
+[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|267x267px]]
 .1 Mutaciones puntuales de ERG11

@@ Line 1: / Line 1: @@
+. Introducción
-−
 Introducción
 Los hongos oportunistas de la especie ''Candida'' han sido asociados con un amplio espectro de infecciones humanas con tasas significativas de morbilidad y mortalidad, que van desde infecciones superficiales de la piel hasta candidiasis profundas o diseminadas, entre las que se encuentran la candidiasis vulvovaginal que afecta aproximadamente al 75% de las mujeres en al menos un episodio en su vida, siendo ocasionada por ''Candida albicans'' (Hel-Houssaini ''et al.,'' 2019).
@@ Line 25: / Line 23: @@
 Tabla 1. Antifúngicos azólicos más comunes.
-[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg]]
+[[File:Orjuela_2019a_5615_Annotation 2020-04-08 223820.jpg|355x355px]]
 .1 Mutaciones puntuales de ERG11

← Older revision		Revision as of 03:45, 9 April 2020
Line 97:		Line 97:

	==5 References==		==5 References==
		+
		+	El-Houssaini, H. H., Elnabawy, O. M., Nasser, H. A., & Elkhatib, W. F. (2019). Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. Microbial pathogenesis, 128, 13-19.
		+
		+	Girão, E., Levin, A. S., Basso, M., Gobara, S., Gomes, L. B., Medeiros, E. A. S., ... & Costa, S. F. (2008). Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999–2003. International Journal of Infectious Diseases, 12(6), e145-e146.
		+
		+	Hoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011). An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrobial agents and chemotherapy, 55(2), 940-942.
		+
		+	Kelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995). Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8, 24 (28)-dien-3β, 6α-diol. Biochemical and biophysical research communications, 207(3), 910-915.
		+
		+	Kohli, A., Smriti, N. F. N., Mukhopadhyay, K., Rattan, A., & Prasad, R. (2002). In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrobial agents and chemotherapy, 46(4), 1046-1052.
		+
		+	Marichal, P., Bossche, H. V., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V., ... & Mose-Larsen, P. (1997). Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy, 41(10), 2229-2237.
		+
		+	Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010). Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagnostic microbiology and infectious disease, 66(4), 373-384.
		+
		+	Mukhopadhyay, K., Prasad, T., Saini, P., Pucadyil, T. J., Chattopadhyay, A., & Prasad, R. (2004). Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrobial Agents and Chemotherapy, 48(5), 1778-1787.
		+
		+	Nikaido, Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria, FASEB J. 12 (1998) 265–274.
		+
		+	Noël, T. (2012). The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. Journal de mycologie medicale, 22(2), 173-178.
		+
		+	Pourakbari, B., Teymuri, M., Mahmoudi, S., K Valian, S., Movahedi, Z., Eshaghi, H., & Mamishi, S. (2017). Expression of Major Efflux Pumps in Fluconazole-Resistant Candida albicans. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 17(3), 178-184.
		+
		+	Selmecki, A., Forche, A., & Berman, J. (2006). Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science, 313(5785), 367-370.
		+
		+	Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012). Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS microbiology reviews, 36(2), 288-305.
		+
		+	Silver, P. M., Oliver, B. G., & White, T. C. (2004). Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryotic Cell, 3(6), 1391-1397.
		+
		+	Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 2003;51:1055–65.
		+
		+	White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial agents and chemotherapy, 41(7), 1482-1487.
		+
		+	Wille, M. P., Guimarães, T., Furtado, G. H. C., & Colombo, A. L. (2013). Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil. Memorias do Instituto Oswaldo Cruz, 108(3), 288-292.
		+
		+	Wirsching, S., Michel, S., & Morschhäuser, J. (2000). Targeted gene disruption in Candida albicans wild‐type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Molecular microbiology, 36(4), 856-865.
		+
		+	Yapar, N., Pullukcu, H., Avkan-Oguz, V., Sayin-Kutlu, S., Ertugrul, B., Sacar, S., ... & Kaya, O. (2011). Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Medical mycology, 49(1), 26-31.

← Older revision		Revision as of 03:30, 9 April 2020
Line 48:		Line 48:

	==3 Bibliography<!--		==3 Bibliography<!--
−	Citations in text will follow a citation-sequence system (i.e. sources are numbered by order of reference so that the first reference cited in the document is [1], the second [2], and so on) with the number of the reference in square brackets. Once a source has been cited, the same number is used in all subsequent references. If the numbers are not in a continuous sequence, use commas (with no spaces) between numbers. If you have more than two numbers in a continuous sequence, use the first and last number of the sequence joined by a hyphen
−
−	You should ensure that all references are cited in the text and that the reference list. References should preferably refer to documents published in Scipedia. Unpublished results should not be included in the reference list, but can be mentioned in the text. The reference data must be updated once publication is ready. Complete bibliographic information for all cited references must be given following the standards in the field (IEEE and ISO 690 standards are recommended). If possible, a hyperlink to the referenced publication should be given. See examples for Scipedia’s articles [1], other publication articles [2], books [3], book chapter [4], conference proceedings [5], and online documents [6], shown in references section below. -->==
−
−

		+	El-Houssaini, H. H., Elnabawy, O. M., Nasser, H. A., & Elkhatib, W. F. (2019). Correlation between antifungal resistance and virulence factors in Candida albicans recovered from vaginal specimens. Microbial pathogenesis, 128, 13-19.
		+
		+	Girão, E., Levin, A. S., Basso, M., Gobara, S., Gomes, L. B., Medeiros, E. A. S., ... & Costa, S. F. (2008). Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999–2003. International Journal of Infectious Diseases, 12(6), e145-e146.
		+
		+	Hoot, S. J., Smith, A. R., Brown, R. P., & White, T. C. (2011). An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrobial agents and chemotherapy, 55(2), 940-942.
		+
		+	Kelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995). Mode of action and resistance to azole antifungals associated with the formation of 14α-methylergosta-8, 24 (28)-dien-3β, 6α-diol. Biochemical and biophysical research communications, 207(3), 910-915.
		+
		+	Kohli, A., Smriti, N. F. N., Mukhopadhyay, K., Rattan, A., & Prasad, R. (2002). In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry. Antimicrobial agents and chemotherapy, 46(4), 1046-1052.
		+
		+	Marichal, P., Bossche, H. V., Odds, F. C., Nobels, G., Warnock, D. W., Timmerman, V., ... & Mose-Larsen, P. (1997). Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents and Chemotherapy, 41(10), 2229-2237.
		+
		+	Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010). Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. Diagnostic microbiology and infectious disease, 66(4), 373-384.
		+
		+	Mukhopadhyay, K., Prasad, T., Saini, P., Pucadyil, T. J., Chattopadhyay, A., & Prasad, R. (2004). Membrane sphingolipid-ergosterol interactions are important determinants of multidrug resistance in Candida albicans. Antimicrobial Agents and Chemotherapy, 48(5), 1778-1787.
		+
		+	Nikaido, Evolutionary origins of multidrug and drug-specific efflux pumps in bacteria, FASEB J. 12 (1998) 265–274.
		+
		+	Noël, T. (2012). The cellular and molecular defense mechanisms of the Candida yeasts against azole antifungal drugs. Journal de mycologie medicale, 22(2), 173-178.
		+
		+	Pourakbari, B., Teymuri, M., Mahmoudi, S., K Valian, S., Movahedi, Z., Eshaghi, H., & Mamishi, S. (2017). Expression of Major Efflux Pumps in Fluconazole-Resistant Candida albicans. Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders), 17(3), 178-184.
		+
		+	Selmecki, A., Forche, A., & Berman, J. (2006). Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science, 313(5785), 367-370.
		+
		+	Silva, S., Negri, M., Henriques, M., Oliveira, R., Williams, D. W., & Azeredo, J. (2012). Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS microbiology reviews, 36(2), 288-305.
		+
		+	Silver, P. M., Oliver, B. G., & White, T. C. (2004). Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryotic Cell, 3(6), 1391-1397.
		+
		+	Van Bambeke F, Glupczynski Y, Plesiat P, Pechere JC, Tulkens PM. Antibiotic efflux pumps in prokaryotic cells: occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 2003;51:1055–65.
		+
		+	White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrobial agents and chemotherapy, 41(7), 1482-1487.
		+
		+	Wille, M. P., Guimarães, T., Furtado, G. H. C., & Colombo, A. L. (2013). Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil. Memorias do Instituto Oswaldo Cruz, 108(3), 288-292.
		+
		+	Wirsching, S., Michel, S., & Morschhäuser, J. (2000). Targeted gene disruption in Candida albicans wild‐type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Molecular microbiology, 36(4), 856-865.
		+
		+	Yapar, N., Pullukcu, H., Avkan-Oguz, V., Sayin-Kutlu, S., Ertugrul, B., Sacar, S., ... & Kaya, O. (2011). Evaluation of species distribution and risk factors of candidemia: a multicenter case-control study. Medical mycology, 49(1), 26-31.

	==4 Acknowledgments<!-- Acknowledgments should be inserted at the end of the document, before the references section. -->==		==4 Acknowledgments<!-- Acknowledgments should be inserted at the end of the document, before the references section. -->==

← Older revision	Revision as of 22:54, 31 May 2019
(No difference)